The evolution of clinical trials: Can we address the challenges of the future?

Abstract

The authors describe key challenges facing the clinical trials community and propose solutions to these issues, including the role the Clinical Trials Transformation Initiative can play in addressing these issues. Specifically, the authors reflect on clinical trial globalization and the harmonization of frameworks and requirements across regions; the challenges associated with balancing the desire for external validity, pragmatic trials, and precision medicine; clinical trial transparency; and operational complexity and the expense of clinical trials. By addressing these challenges, future clinical trials will be more feasible, relevant, and credible, and support both the continuing altruistic contributions of patients and the collection of more meaningful data.

Keywords

clinical trials globalization good clinical practice trial data sharing

Get full access to this article

View all access options for this article.

References

Marshall

Blacklock

Cameron

et al . Streptomycin treatment of pulmonary tuberculosis: a medical research council investigation. Br Med J 1948; 2: 769–782.

Berry

. The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol 2015; 9: 951–959.

Berry

Connor

Lewis

. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015; 313: 1619–1620.

Clinical Trials Transformation Initiative. Developing novel endpoints generated by mobile technology for use in clinical trials, http://www.ctti-clinicaltrials.org/projects/novel-endpoints (accessed 10 July 2017).

International Council for Harmonisation. Technical requirements for pharmaceuticals for human use, http://www.ich.org/home.html (accessed 16 July 2017).

Penkov

Tomasi

Eichler

et al . Pediatric medicine development: an overview and comparison of regulatory processes in the European Union and United States. Ther Innov Regul Sci 2017; 51: 360–371.

European Medicines Agency. EMA and FDA encourage use of innovative approaches in the development of medicines for Gaucher disease, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/07/news_detail_002770.jsp&mid=WC0b01ac058004d5c1 (accessed 16 July 2017).

European Medicines Agency. Regulators in EU, Japan and US take steps to facilitate development of new antibiotics, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/06/news_detail_002763.jsp&mid=WC0b01ac058004d5c1 (accessed 16 July 2017).

European Medicines Agency. Workshop: addressing unmet needs of children with pulmonary arterial hypertension, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/06/news_detail_002760.jsp&mid=WC0b01ac058004d5c1 (accessed 12 October 2017).

10.

Viele

Berry

Neuenschwander

et al . Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat 2014; 13: 41–54.

11.

European Medicines Agency. Reflection paper on the use of extrapolation in the development of medicines for paediatrics, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/10/WC500236640.pdf (accessed 11 October 2017).

12.

International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Addendum to ICH E11: clinical investigation of medicinal products in the paediatric population, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/ICH_E11_R1_Step_2_25Aug2016_Final.pdf (2016, accessed 11 October 2017).

13.

Eichler

Abadie

Breckenridge

et al . Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov 2011; 10: 495–506.

14.

Thorpe

Zwarenstein

Oxman

et al . A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009; 62: 464–475.

15.

Selker

Oye

Eichler

et al . A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials. Clin Pharmacol Ther 2014; 95: 147–153.

16.

Maloney

. A new paradigm. “Learn—learn more”; dose-exposure-response at the center of drug development and regulatory approval. Clin Pharmacol Ther 2017; 102: 942–950.

17.

Clinical Trials Transformation Initiative. CTTI recommendations: registry trials, http://www.ctti-clinicaltrials.org/files/recommendations/registrytrials-recs.pdf (accessed 18 July 2017).

18.

Innovative Medicines Initiative. Get real: new methods for real world evidence collection and synthesis, http://www.imi-getreal.eu (accessed 16 July 2017).

19.

Clinical Trials Transformation Initiative, http://www.ctti-clinicaltrials.org (accessed 18 July 2017).

20.

Sekeres

. Contract research agonizations. Editor’s corner, perspectives. ASH Clinical News, 2017, https://www.ashclinicalnews.org/perspectives/editors-corner/contract-research-agonizations/ (accessed 21 December 2017).

21.

LeGouill

. Advocating for a return to common sense in clinical research. Editor’s corner, perspectives, from our readers. ASH Clinical News, 2017, https://www.ashclinicalnews.org/perspectives/advocating-return-common-sense-clinical-research/ (accessed 21 December 2017).

22.

Landray

Bax

Alliot

et al . Improving public health by improving clinical trial guidelines and their application. Eur Heart J 2017; 38: 1632–1637.

23.

International Council for Harmonisation. ICH reflection on “GCP renovation”: modernization of ICH E8 and subsequent renovation of ICH E6, 2017, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/GCP_Renovation/ICH_Reflection_paper_GCP_Renovation_Jan_2017_Final.pdf (accessed 10 October 2017).

24.

Bertagnoll

Khozin

Murphy

. Data-sharing models. N Engl J Med 2017; 376: 2305–2306.

25.

Eichler

Bloechl-Daum

Bauer

et al . “Threshold-crossing”: a useful way to establish the counterfactual in clinical trials? Clin Pharmacol Ther 2016; 100: 699–712.

26.

Burns

Miller

. Learning what we didn’t know: the SPRINT data analysis challenge. N Engl J Med 2017; 376: 2205–2207.